‘Signature’ genes could determine immunotherapy success
Scientists have identified a set of ‘signature’ genes that can determine the success of immune cells inside cancer tumours.
Research published in Nature Communications reveals that scientists at the University of Tokyo, Japan identified whether CD8+ T cells, a type of immune cell, will multiply or stall within cancer tumours. The findings provide a powerful pan-immunotherapy biomarker for treatment monitoring and could pave the way for next-generation immunodynamic therapies.
The ability of CD8+ T cells to rapidly proliferate inside tumours is crucial to the success of cancer immunotherapy. However, the factors and mechanisms driving this burst in proliferation remain poorly understood, making it difficult to predict which patients will benefit from treatment. A deeper understanding of this T cell burst could also guide the development of new therapies that enhance T cell proliferation and improve treatment outcomes.
The study reveals that an international team of researchers, led by Associate Professor Satoshi Ueha and Professor Kouji Matsushima from the Research Institute for Biomedical Sciences, Tokyo University of Science (TUS), Japan, developed a novel approach to monitor CD8⁺ T cell activity over time.
“Our work opens the door to a dynamic understanding of how immunotherapies succeed or fail in real time,” said Ueha. “We hope that the expansion signature can serve not only as a predictor of treatment response but also as a guide for designing new therapies that can reawaken the immune system when it begins to falter. Ultimately, this could bring us closer to truly personalised immunotherapy.”
Research paving the way for new therapies
Researchers developed the novel approach by creating a ‘multi-site tumour model’ in mice, implanting tumours at different anatomical locations to allow for sequential sampling of T cells over time. By using unique T cell receptor (TCR) sequences as natural barcodes, the team tracked hundreds of individual CD8⁺ T cell clones as they expanded or contracted over a week. This led to a dynamic, clonal-level view of the immune response to cancer that had previously been out of reach.
Using next-generation single-cell RNA and TCR sequencing, the team discovered that expanding T cells consistently expressed a specific set of genes prior to proliferation. This coordinated gene set, called the ‘expansion signature’, could identify T cells that were primed for growth.
The expansion signature proved to be a strong predictor of T cell expansion in both untreated and immunotherapy-treated mice, including those receiving programmed cell death-ligand protein 1 and cytotoxic T-lymphocyte associated protein 4 or lymphocyte activation gene-3 (LAG-3) checkpoint blockade therapy. Its expression in human patients receiving various immunotherapies, including programmed cell death protein 1 blockade and chimeric antigen receptor-T cell therapy, correlated with improved survival outcomes.
While the expression of expansion signature faded over time, prior to T cell contraction, researchers found that a specific population of T cells with the potential to reignite expansion remained within the tumour. To test this, the team administered LAG-3 blockade and observed reactivation of the expansion signature along with renewed proliferation of previously contracted T cell clones.
These findings position the expansion signature as a powerful pan-immunotherapy biomarker for tracking, predicting, and potentially reinvigorating the anti-tumour T cell response.
Researchers hope the expansion signature will ultimately pave the way for the development of new therapies that modulate immune cell dynamics. Tuning T cell proliferation provides a granular control of the immune response that could both maximise treatment efficacy and minimise the effect of adverse events.
Bruno Quinney, Content Team, DDW
